Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms

Hideaki Niiyama, Kazuhiro Mizumoto, Masahiro Kusumoto, Takahiro Ogawa, Nobuhiro Suehara, Hideo Shimura, Masao Tanaka

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

BACKGROUND. Telomerase activity has been reported to have potential as a useful diagnostic marker for cancer in various organs. The authors previously reported that telomerase activity in pancreatic juice differentiates pancreatic ductal carcinoma from adenoma and pancreatitis. In the current study, the usefulness of semiquantitatively determined telomerase activity in the diagnosis of malignant biliary tract neoplasms was investigated. METHODS. The samples examined included 61 surgically resected biliary tract tissues (11 gallbladder carcinomas, 5 bile duct carcinomas, 1 gallbladder adenoma, 30 cholecytitis cases, 7 cholesterol polyps, 1 normal gallbladder, and 6 normal common bile duct tissues), 42 bile samples from patients with biliary tract or pancreatic disease (19 cases of malignant biliary tract disease, 11 cases of benign biliary tract disease, 10 cases of malignant pancreatic disease, and 2 cases of benign pancreatic disease), and 14 bile duct biopsy specimens collected by percutaneous transhepatic choledochoscopy or endoscopic retrograde cholangiopan-creatography (8 bile duct carcinoma specimens, 1 bile duct adenoma specimen, and 5 hepatolithiasis specimens). RESULTS. In biliary tract tissues, a telomerase ladder was detected in 73% of gallbladder carcinomas, 40% of bile duct carcinomas, and none of the other biliary tract tissues. One gallbladder adenoma showed a weak telomerase ladder. The telomerase ladder was detected in the bile sample from 1 patient (5.3%) with malignant biliary tract disease, none of the patients with benign biliary tract disease, 5 patients (50%) with malignant pancreatic disease, and none of the patients with benign pancreatic disease. In biopsy specimens, the telomerase ladder was detected in 75% of patients with bile duct carcinoma but not in any of the patients with hepatolithiasis. The median value of relative telomerase activity in the patients with bile duct carcinoma was significantly higher than that in the patients with hepatolithiasis. The diagnosis of bile duct carcinoma was confirmed preoperatively by histopathologic examination in only 25% of the biopsy specimens. CONCLUSIONS. The results of the current study indicate that telomerase is highly activated in biliary tract carcinomas and that the detection of a telomerase ladder in biopsy samples is an excellent tool for the diagnosis of bile duct carcinomas.

Original languageEnglish
Pages (from-to)2138-2143
Number of pages6
JournalCancer
Volume85
Issue number10
DOIs
Publication statusPublished - May 15 1999

Fingerprint

Biliary Tract Neoplasms
Telomerase
Bile Ducts
Biliary Tract Diseases
Carcinoma
Biopsy
Pancreatic Diseases
Gallbladder
Biliary Tract
Adenoma
Bile
Bile Duct Adenoma
Pancreatic Ductal Carcinoma
Pancreatic Juice
Common Bile Duct
Polyps
Pancreatitis
Cholesterol

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms. / Niiyama, Hideaki; Mizumoto, Kazuhiro; Kusumoto, Masahiro; Ogawa, Takahiro; Suehara, Nobuhiro; Shimura, Hideo; Tanaka, Masao.

In: Cancer, Vol. 85, No. 10, 15.05.1999, p. 2138-2143.

Research output: Contribution to journalArticle

Niiyama, Hideaki ; Mizumoto, Kazuhiro ; Kusumoto, Masahiro ; Ogawa, Takahiro ; Suehara, Nobuhiro ; Shimura, Hideo ; Tanaka, Masao. / Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms. In: Cancer. 1999 ; Vol. 85, No. 10. pp. 2138-2143.
@article{a32908edf95847cdb1c6d6948394d458,
title = "Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms",
abstract = "BACKGROUND. Telomerase activity has been reported to have potential as a useful diagnostic marker for cancer in various organs. The authors previously reported that telomerase activity in pancreatic juice differentiates pancreatic ductal carcinoma from adenoma and pancreatitis. In the current study, the usefulness of semiquantitatively determined telomerase activity in the diagnosis of malignant biliary tract neoplasms was investigated. METHODS. The samples examined included 61 surgically resected biliary tract tissues (11 gallbladder carcinomas, 5 bile duct carcinomas, 1 gallbladder adenoma, 30 cholecytitis cases, 7 cholesterol polyps, 1 normal gallbladder, and 6 normal common bile duct tissues), 42 bile samples from patients with biliary tract or pancreatic disease (19 cases of malignant biliary tract disease, 11 cases of benign biliary tract disease, 10 cases of malignant pancreatic disease, and 2 cases of benign pancreatic disease), and 14 bile duct biopsy specimens collected by percutaneous transhepatic choledochoscopy or endoscopic retrograde cholangiopan-creatography (8 bile duct carcinoma specimens, 1 bile duct adenoma specimen, and 5 hepatolithiasis specimens). RESULTS. In biliary tract tissues, a telomerase ladder was detected in 73{\%} of gallbladder carcinomas, 40{\%} of bile duct carcinomas, and none of the other biliary tract tissues. One gallbladder adenoma showed a weak telomerase ladder. The telomerase ladder was detected in the bile sample from 1 patient (5.3{\%}) with malignant biliary tract disease, none of the patients with benign biliary tract disease, 5 patients (50{\%}) with malignant pancreatic disease, and none of the patients with benign pancreatic disease. In biopsy specimens, the telomerase ladder was detected in 75{\%} of patients with bile duct carcinoma but not in any of the patients with hepatolithiasis. The median value of relative telomerase activity in the patients with bile duct carcinoma was significantly higher than that in the patients with hepatolithiasis. The diagnosis of bile duct carcinoma was confirmed preoperatively by histopathologic examination in only 25{\%} of the biopsy specimens. CONCLUSIONS. The results of the current study indicate that telomerase is highly activated in biliary tract carcinomas and that the detection of a telomerase ladder in biopsy samples is an excellent tool for the diagnosis of bile duct carcinomas.",
author = "Hideaki Niiyama and Kazuhiro Mizumoto and Masahiro Kusumoto and Takahiro Ogawa and Nobuhiro Suehara and Hideo Shimura and Masao Tanaka",
year = "1999",
month = "5",
day = "15",
doi = "10.1002/(SICI)1097-0142(19990515)85:10<2138::AID-CNCR7>3.0.CO;2-8",
language = "English",
volume = "85",
pages = "2138--2143",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms

AU - Niiyama, Hideaki

AU - Mizumoto, Kazuhiro

AU - Kusumoto, Masahiro

AU - Ogawa, Takahiro

AU - Suehara, Nobuhiro

AU - Shimura, Hideo

AU - Tanaka, Masao

PY - 1999/5/15

Y1 - 1999/5/15

N2 - BACKGROUND. Telomerase activity has been reported to have potential as a useful diagnostic marker for cancer in various organs. The authors previously reported that telomerase activity in pancreatic juice differentiates pancreatic ductal carcinoma from adenoma and pancreatitis. In the current study, the usefulness of semiquantitatively determined telomerase activity in the diagnosis of malignant biliary tract neoplasms was investigated. METHODS. The samples examined included 61 surgically resected biliary tract tissues (11 gallbladder carcinomas, 5 bile duct carcinomas, 1 gallbladder adenoma, 30 cholecytitis cases, 7 cholesterol polyps, 1 normal gallbladder, and 6 normal common bile duct tissues), 42 bile samples from patients with biliary tract or pancreatic disease (19 cases of malignant biliary tract disease, 11 cases of benign biliary tract disease, 10 cases of malignant pancreatic disease, and 2 cases of benign pancreatic disease), and 14 bile duct biopsy specimens collected by percutaneous transhepatic choledochoscopy or endoscopic retrograde cholangiopan-creatography (8 bile duct carcinoma specimens, 1 bile duct adenoma specimen, and 5 hepatolithiasis specimens). RESULTS. In biliary tract tissues, a telomerase ladder was detected in 73% of gallbladder carcinomas, 40% of bile duct carcinomas, and none of the other biliary tract tissues. One gallbladder adenoma showed a weak telomerase ladder. The telomerase ladder was detected in the bile sample from 1 patient (5.3%) with malignant biliary tract disease, none of the patients with benign biliary tract disease, 5 patients (50%) with malignant pancreatic disease, and none of the patients with benign pancreatic disease. In biopsy specimens, the telomerase ladder was detected in 75% of patients with bile duct carcinoma but not in any of the patients with hepatolithiasis. The median value of relative telomerase activity in the patients with bile duct carcinoma was significantly higher than that in the patients with hepatolithiasis. The diagnosis of bile duct carcinoma was confirmed preoperatively by histopathologic examination in only 25% of the biopsy specimens. CONCLUSIONS. The results of the current study indicate that telomerase is highly activated in biliary tract carcinomas and that the detection of a telomerase ladder in biopsy samples is an excellent tool for the diagnosis of bile duct carcinomas.

AB - BACKGROUND. Telomerase activity has been reported to have potential as a useful diagnostic marker for cancer in various organs. The authors previously reported that telomerase activity in pancreatic juice differentiates pancreatic ductal carcinoma from adenoma and pancreatitis. In the current study, the usefulness of semiquantitatively determined telomerase activity in the diagnosis of malignant biliary tract neoplasms was investigated. METHODS. The samples examined included 61 surgically resected biliary tract tissues (11 gallbladder carcinomas, 5 bile duct carcinomas, 1 gallbladder adenoma, 30 cholecytitis cases, 7 cholesterol polyps, 1 normal gallbladder, and 6 normal common bile duct tissues), 42 bile samples from patients with biliary tract or pancreatic disease (19 cases of malignant biliary tract disease, 11 cases of benign biliary tract disease, 10 cases of malignant pancreatic disease, and 2 cases of benign pancreatic disease), and 14 bile duct biopsy specimens collected by percutaneous transhepatic choledochoscopy or endoscopic retrograde cholangiopan-creatography (8 bile duct carcinoma specimens, 1 bile duct adenoma specimen, and 5 hepatolithiasis specimens). RESULTS. In biliary tract tissues, a telomerase ladder was detected in 73% of gallbladder carcinomas, 40% of bile duct carcinomas, and none of the other biliary tract tissues. One gallbladder adenoma showed a weak telomerase ladder. The telomerase ladder was detected in the bile sample from 1 patient (5.3%) with malignant biliary tract disease, none of the patients with benign biliary tract disease, 5 patients (50%) with malignant pancreatic disease, and none of the patients with benign pancreatic disease. In biopsy specimens, the telomerase ladder was detected in 75% of patients with bile duct carcinoma but not in any of the patients with hepatolithiasis. The median value of relative telomerase activity in the patients with bile duct carcinoma was significantly higher than that in the patients with hepatolithiasis. The diagnosis of bile duct carcinoma was confirmed preoperatively by histopathologic examination in only 25% of the biopsy specimens. CONCLUSIONS. The results of the current study indicate that telomerase is highly activated in biliary tract carcinomas and that the detection of a telomerase ladder in biopsy samples is an excellent tool for the diagnosis of bile duct carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0033562846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033562846&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990515)85:10<2138::AID-CNCR7>3.0.CO;2-8

DO - 10.1002/(SICI)1097-0142(19990515)85:10<2138::AID-CNCR7>3.0.CO;2-8

M3 - Article

C2 - 10326691

AN - SCOPUS:0033562846

VL - 85

SP - 2138

EP - 2143

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -